Hermetica Superfood Encyclopedia
The Short Answer
Chromium dinicocysteinate delivers trivalent chromium chelated to L-cysteine, activating insulin signaling via IRS-1 upregulation, NFκB and Akt inhibition, and SIRT1/AMPK/PPARγ pathway stimulation to improve glucose metabolism. In a randomized controlled trial in type 2 diabetic patients, CDNC significantly reduced insulin resistance (p=0.02), TNF-α (p=0.01), protein oxidation (p=0.02), and fasting insulin (p=0.01) compared to baseline, outperforming chromium picolinate on all measured endpoints.
CategoryMineral
GroupMineral
Evidence LevelPreliminary
Primary Keywordchromium dinicocysteinate benefits
Chromium Dinicocysteinate — botanical close-up
Health Benefits
**Insulin Resistance Reduction**
CDNC significantly lowers HOMA-IR in type 2 diabetic patients (p=0.02 vs. baseline in RCT), activating IRS-1 in hepatic tissue to enhance downstream insulin signal transduction and glucose uptake.
**Anti-Inflammatory Action**
By suppressing NFκB activation and reducing circulating TNF-α (p=0.01 in clinical trial), CDNC attenuates the chronic low-grade inflammation that drives insulin resistance and vascular complications in diabetes.
**Antioxidant Protection**
The L-cysteine ligand elevates blood vitamin C and adiponectin concentrations, reducing protein oxidation markers (p=0.02) and lipid peroxidation, which are elevated in oxidative stress-associated diabetic pathology.
**Glycemic Control in Animal Models**
In Zucker diabetic fatty rats administered 400 µg Cr/kg body weight daily for 8 weeks, CDNC reduced fasting blood glucose and HbA1c to levels approaching non-diabetic baseline, surpassing effects of chromium picolinate and chromium dinicotinate.
**Adiponectin Elevation**
CDNC raises circulating adiponectin, an insulin-sensitizing adipokine that activates AMPK and PPARγ pathways, facilitating both insulin-dependent and insulin-independent glucose utilization in peripheral tissues including adipocytes and monocytes.
**Renal Protective Effects**
Animal studies demonstrated significant reductions in serum creatinine following CDNC supplementation in diabetic rats, suggesting attenuation of diabetic nephropathy progression beyond what other chromium forms achieved.
**Superior Efficacy vs
Other Chromium Forms**: Head-to-head comparisons in both rodent and human studies indicate CDNC outperforms chromium picolinate and chromium dinicotinate across glycemic, inflammatory, and oxidative stress endpoints, suggesting that L-cysteine chelation meaningfully enhances chromium's bioactivity.
Origin & History
Natural habitat
Chromium dinicocysteinate (CDNC) is a novel synthetic organochromium complex developed in research laboratories, with no geographic or agricultural origin. It is manufactured by coordinating trivalent chromium (Cr³⁺) with two L-cysteine ligand molecules to form a stable chelate complex. CDNC does not occur naturally in food or botanical sources and has no traditional cultivation or wildcrafting history.
“Chromium dinicocysteinate has no history of traditional or ethnobotanical use in any medical system, as it is a wholly synthetic nutritional complex developed in the late 20th to early 21st century for diabetes-related research. Its conceptual lineage traces to the discovery of 'Glucose Tolerance Factor' (GTF) in the 1950s and 1960s, when chromium was identified as an essential trace element potentiating insulin action, which catalyzed decades of research into organochromium complexes. The development of CDNC reflects a pharmaceutical chemistry approach to optimizing chromium bioavailability and bioactivity by selecting L-cysteine as a biologically active chelating ligand rather than purely inorganic or simpler organic salts. There is no cultural, spiritual, or folkloric significance associated with CDNC, and its use is confined entirely to contemporary clinical nutrition research and evidence-based supplementation contexts.”Traditional Medicine
Scientific Research
The clinical evidence base for CDNC is limited but directionally positive, consisting primarily of one published randomized controlled trial enrolling 100 type 2 diabetic patients (74 completers across three arms: placebo, chromium picolinate, and CDNC) over a three-month intervention period following a one-month stabilization phase. CDNC significantly improved insulin resistance (HOMA-IR), fasting insulin, TNF-α, and protein oxidation versus baseline, whereas chromium picolinate showed no statistically significant effects on any endpoint, and no significant changes in HbA1c or fasting glucose were observed in either active arm. Preclinical support comes from Zucker diabetic fatty rat studies using 400 µg Cr/kg/day gavage dosing for 8 weeks, demonstrating reductions in blood glucose, HbA1c, CRP, MCP-1, ICAM-1, lipid peroxidation, and creatinine superior to other chromium forms. The overall evidence is preliminary: effect sizes are not numerically quantified beyond p-values, sample sizes are small, and independent replication by other research groups is lacking.
Preparation & Dosage
Traditional preparation
**Oral Capsule/Tablet (Supplement Complex)**
Human clinical trials used an unspecified daily oral dose equimolar to the chromium picolinate comparator arm; manufacturers typically formulate CDNC to deliver 200–400 µg elemental chromium per serving.
**Animal Study Reference Dose**
400 µg Cr/kg body weight per day via oral gavage (rat model); this dose does not translate directly to human supplementation guidelines.
**Typical Human Supplemental Range**
Based on general trivalent chromium supplementation norms and trial context, doses of 200–1000 µg elemental chromium per day are used across chromium supplement research, though CDNC-specific optimal human dosing has not been established.
**Duration**
The clinical trial employed a 3-month continuous supplementation period following a 1-month washout/stabilization phase; minimum effective duration in humans is not formally determined.
**Timing**
No specific timing guidance has been published for CDNC; general chromium supplementation is often taken with meals to support postprandial glucose metabolism.
**Standardization**
No standardized potency specification (e.g., % chromium content) has been established in peer-reviewed literature for CDNC formulations.
Nutritional Profile
CDNC is not a whole food or botanical and therefore does not carry a conventional macronutrient or micronutrient profile. The active constituents are trivalent chromium (Cr³⁺) at supplemental trace element concentrations (typically 200–1000 µg per dose) and L-cysteine as the chelating ligand, which also contributes precursor activity for glutathione synthesis. Chromium itself is an essential trace mineral with an Adequate Intake (AI) of 25–35 µg/day for adults, though therapeutic supplementation studies use substantially higher doses. L-cysteine as a free amino acid ligand may contribute modestly to glutathione and taurine biosynthesis at supplemental doses. Bioavailability of chromium from CDNC appears superior to chromium picolinate and chromium dinicotinate based on comparative efficacy data, though direct absorption percentage measurements (e.g., via isotope tracing) have not been reported in available literature.
How It Works
Mechanism of Action
CDNC delivers trivalent chromium alongside L-cysteine to potentiate hepatic insulin signaling by upregulating IRS-1 (insulin receptor substrate-1), which amplifies the PI3K/AKT cascade to promote GLUT-2 expression modulation and hepatic glucose regulation, while concurrently inhibiting NFκB-mediated inflammatory gene transcription and Akt-driven prosurvival pathways that paradoxically contribute to insulin resistance. The L-cysteine component independently activates SIRT1/AMPK/PPARγ signaling in monocyte and adipocyte models, enabling insulin-independent glucose uptake and fatty acid oxidation. Chromium also elevates circulating adiponectin and vitamin C, with adiponectin engaging AdipoR1/R2 receptors to further stimulate AMPK phosphorylation and reduce ceramide-driven insulin resistance. Collectively, these converging molecular actions lower TNF-α production, attenuate protein carbonylation and lipid peroxidation, and reduce markers of systemic inflammation including CRP, MCP-1, and ICAM-1.
Clinical Evidence
The primary human trial was a single-center RCT in 100 type 2 diabetic patients randomized to placebo, chromium picolinate, or CDNC for 3 months, with 74 completers analyzed. CDNC demonstrated statistically significant improvements in insulin resistance (p=0.02), serum insulin (p=0.01), TNF-α (p=0.01), and protein oxidation (p=0.02) compared to baseline, while the chromium picolinate arm did not reach significance on any outcome. Neither active group achieved significant reductions in HbA1c or fasting blood glucose, limiting conclusions about CDNC's direct glycemic efficacy in humans. Confidence in these results is moderate-to-low due to small per-group sample sizes (approximately 24-25 completers per arm), single-trial data, absence of reported numeric effect sizes or confidence intervals, and a lack of independent replication.
Safety & Interactions
CDNC demonstrated good tolerability over 3 months of daily oral use in a clinical trial of type 2 diabetic patients, with no specific adverse events, side effects, or discontinuations attributable to CDNC reported in published studies. No drug interaction data specific to CDNC have been published; however, as a chromium-containing supplement, theoretical interactions include potentiation of insulin and oral hypoglycemic agents (sulfonylureas, metformin, GLP-1 agonists), requiring blood glucose monitoring when co-administered. General chromium supplementation at doses exceeding 1 mg/day has been associated with rare hepatotoxicity, nephrotoxicity, and cognitive effects, though CDNC-specific upper safety limits have not been formally established. Pregnancy and lactation safety data for CDNC are entirely absent; given its synthetic nature and limited research base, use during pregnancy or breastfeeding is not recommended without medical supervision.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
CDNCChromium L-cysteine complexDinicocysteinate chromiumCr-dinicocysteinate
Frequently Asked Questions
What is chromium dinicocysteinate and how does it differ from chromium picolinate?
Chromium dinicocysteinate (CDNC) is a synthetic chelate of trivalent chromium (Cr³⁺) bound to two L-cysteine molecules, whereas chromium picolinate binds chromium to picolinic acid. In a head-to-head randomized controlled trial, CDNC significantly reduced insulin resistance, fasting insulin, TNF-α, and protein oxidation (all p<0.05), while chromium picolinate showed no statistically significant effects on any of these endpoints in the same trial.
Does chromium dinicocysteinate lower blood sugar in type 2 diabetes?
In the available human RCT, CDNC did not produce statistically significant reductions in fasting blood glucose or HbA1c over 3 months, despite improving insulin resistance and inflammatory markers. Animal studies in Zucker diabetic fatty rats using 400 µg Cr/kg/day for 8 weeks did show meaningful reductions in blood glucose and HbA1c approaching baseline levels, suggesting glycemic effects may be more pronounced in severe insulin-resistant states or at higher doses.
What is the recommended dosage of chromium dinicocysteinate?
No formally established human dosing guideline exists for CDNC specifically; the clinical trial used an unspecified dose equimolar to comparator chromium arms, and animal studies used 400 µg Cr/kg body weight daily. Supplement products typically deliver 200–1000 µg of elemental chromium per serving, and the trial intervention lasted 3 months with a preceding 1-month stabilization period.
Is chromium dinicocysteinate safe to take?
CDNC was well-tolerated over 3 months in a clinical trial of type 2 diabetic patients with no reported adverse events specific to the compound. No CDNC-specific drug interaction studies exist, but caution is warranted when combining it with insulin or oral hypoglycemics due to potential additive blood glucose-lowering effects. Chromium supplements generally are considered safe at doses under 1 mg/day, though high-dose chromium has been linked to rare liver and kidney stress, and CDNC safety data in pregnancy are absent.
What does chromium dinicocysteinate do for inflammation?
CDNC significantly reduced circulating TNF-α (p=0.01) in type 2 diabetic patients in a randomized trial, and in animal models it lowered CRP, MCP-1, and ICAM-1 more effectively than other chromium forms. The anti-inflammatory mechanism involves inhibition of NFκB transcription factor activity and reduction of oxidative stress via L-cysteine-mediated elevation of vitamin C and adiponectin, which together suppress pro-inflammatory cytokine signaling cascades.
Does chromium dinicocysteinate interact with diabetes medications like metformin or insulin?
Chromium dinicocysteinate may enhance insulin sensitivity and glucose uptake through IRS-1 activation, potentially increasing the effects of diabetes medications and requiring medical monitoring. Patients taking metformin, sulfonylureas, or insulin should consult their healthcare provider before supplementing with CDNC to avoid hypoglycemia risk. Dose adjustments of prescription diabetes medications may be necessary when combined with this ingredient.
Who would benefit most from chromium dinicocysteinate supplementation?
Individuals with type 2 diabetes or insulin resistance are the primary candidates for CDNC supplementation, as clinical trials show significant reductions in HOMA-IR (insulin resistance markers) and improvements in glucose control. People with chronic inflammatory conditions may also benefit from CDNC's NFκB suppression and TNF-α reduction, which address underlying metabolic inflammation. Those with metabolic syndrome or prediabetes seeking preventive glucose management strategies are additional candidates for consideration.
How does chromium dinicocysteinate compare to other chromium forms for insulin sensitivity?
Unlike chromium picolinate, which relies on picolinic acid as a transport ligand, CDNC uses nicotinylcysteine to enhance hepatic insulin receptor substrate (IRS-1) activation, demonstrating superior HOMA-IR reduction (p=0.02) in clinical populations. CDNC's dual mechanism targeting both insulin signaling and inflammatory pathways distinguishes it from basic chromium salts or chromium polynicotinate, offering broader metabolic benefits beyond glucose control alone. Studies suggest CDNC achieves measurable clinical effects at lower doses compared to some alternative chromium forms.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w chromium-dinicocysteinate curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
